Oncogenex Pharma (OGXI) 0.89 $OGXI
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.27 (+0.01), OGXI: 0.89 (unch), AMGN: 174.14 (+2.11), LLY: 83.45 (+0.56), BMY: 75.84 (+1.03), MNTA: 11.43 (+0.17), CELG: 114.09 (+1.90), EXEL: 9.25 (+0.07)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
CNW Group - Thu May 12, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)
OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
PR Newswire - Thu Apr 28, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.
OGXI: 0.89 (unch)
Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)
ACCESSWIRE - Tue Apr 26, 1:05PM CDT
BOTHELL, WA and VANCOUVER, BC / ACCESSWIRE / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI's securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.
OGXI: 0.89 (unch)
Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.89 (unch), UPL: 0.31 (unch), CPLP: 3.65 (-0.12), LPTN: 1.93 (-0.02)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.45 (-0.03), OGXI: 0.89 (unch), SEED: 2.15 (-0.02), TCS: 5.44 (-0.09)
OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 3:02PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
OGXI: 0.89 (unch)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015
PR Newswire - Wed Mar 09, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced year end 2015 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)
OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
CNW Group - Thu Feb 04, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OGXI: 0.89 (unch)
OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 11:50AM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen failed to achieve the primary endpoint in an ongoing mid-stage study for NSCLC.
IMDZ: 7.55 (-0.12), EARS: 4.16 (+0.15), OGXI: 0.89 (unch), CORT: 5.89 (+0.09)
OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
PR Newswire - Wed Jan 20, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce(TM) trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
OGXI: 0.89 (unch)
Market Influences That Drive Equities Forward - New Research on Lionbridge Technologies, Ceres, Tejon Ranch and OncoGenex Pharmaceuticals
ACCESSWIRE - Fri Dec 18, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lionbridge Technologies Inc. (NASDAQ: LIOX), Ceres Inc. (NASDAQ: CERE), Tejon Ranch Co. (NYSE: TRC) and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TRC: 26.50 (+0.23), OGXI: 0.89 (unch), CERE: 0.40 (unch), LIOX: 4.52 (+0.01)
OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis
PR Newswire - Wed Dec 09, 6:00AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the independent Data Safety Monitoring Board (DSMB) at Dana-Farber/Harvard Cancer Center has recommended that the Phase 2 Borealis-2(TM) trial continue as planned after completing the pre-specified futility analysis.
OGXI: 0.89 (unch)
OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses
PR Newswire - Tue Dec 01, 3:01PM CST
Final Results Expected in Second Half of 2016
OGXI: 0.89 (unch)
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.27 (+0.01), OGXI: 0.89 (unch), AMGN: 174.14 (+2.11), LLY: 83.45 (+0.56), BMY: 75.84 (+1.03), MNTA: 11.43 (+0.17), CELG: 114.09 (+1.90), EXEL: 9.25 (+0.07)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
CNW Group - Thu May 12, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)
OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
PR Newswire - Thu Apr 28, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.
OGXI: 0.89 (unch)
Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)
ACCESSWIRE - Tue Apr 26, 1:05PM CDT
BOTHELL, WA and VANCOUVER, BC / ACCESSWIRE / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI's securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.
OGXI: 0.89 (unch)
Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.89 (unch), UPL: 0.31 (unch), CPLP: 3.65 (-0.12), LPTN: 1.93 (-0.02)
These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.45 (-0.03), OGXI: 0.89 (unch), SEED: 2.15 (-0.02), TCS: 5.44 (-0.09)
OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 3:02PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
OGXI: 0.89 (unch)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015
PR Newswire - Wed Mar 09, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced year end 2015 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)
OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
CNW Group - Thu Feb 04, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OGXI: 0.89 (unch)
OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 11:50AM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen failed to achieve the primary endpoint in an ongoing mid-stage study for NSCLC.
IMDZ: 7.55 (-0.12), EARS: 4.16 (+0.15), OGXI: 0.89 (unch), CORT: 5.89 (+0.09)
OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
PR Newswire - Wed Jan 20, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce(TM) trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
OGXI: 0.89 (unch)
Market Influences That Drive Equities Forward - New Research on Lionbridge Technologies, Ceres, Tejon Ranch and OncoGenex Pharmaceuticals
ACCESSWIRE - Fri Dec 18, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lionbridge Technologies Inc. (NASDAQ: LIOX), Ceres Inc. (NASDAQ: CERE), Tejon Ranch Co. (NYSE: TRC) and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TRC: 26.50 (+0.23), OGXI: 0.89 (unch), CERE: 0.40 (unch), LIOX: 4.52 (+0.01)
OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis
PR Newswire - Wed Dec 09, 6:00AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the independent Data Safety Monitoring Board (DSMB) at Dana-Farber/Harvard Cancer Center has recommended that the Phase 2 Borealis-2(TM) trial continue as planned after completing the pre-specified futility analysis.
OGXI: 0.89 (unch)
OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses
PR Newswire - Tue Dec 01, 3:01PM CST
Final Results Expected in Second Half of 2016
OGXI: 0.89 (unch)
